Abstract
Chronic hepatitis can resolve spontaneously or progress to more advanced stages, i.e. fibrosis, cirrhosis, and liver cancer, respectively. Two million deaths each year are attributed to liver diseases globally. Chronic liver disease and cirrhosis comprise 11th position in leading causes of death worldwide. Viral infections account for the etiologic factor of most cases of hepatitis. Almost the only available way for the treatment of end stages of hepatitis is liver transplantation. The biggest problem with this therapeutic approach is the number of liver transplant donors is less than the number of recipients. Therefore, more advanced methods must investigate. Recently, gene therapy by the utilization of stem cells yielded promising results in clinical and preclinical investigations to the treatment of liver diseases. Novel genome editing tools such as TALENs and CRISPR/Cas9 consider as powerful genome correction approaches and can employe for iPSCs gene editing. This paper highlights the various aspects of gene therapy through stem cells for liver diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
